Overexpression of calreticulin in malignant and benign breast tumors: relationship with humoral immunity

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F12%3A00378925" target="_blank" >RIV/61388971:_____/12:00378925 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1159/000335267" target="_blank" >http://dx.doi.org/10.1159/000335267</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1159/000335267" target="_blank" >10.1159/000335267</a>

Result language
angličtina
Original language name
Overexpression of calreticulin in malignant and benign breast tumors: relationship with humoral immunity
Original language description
Calreticulin is a multicompartmental protein which regulates many important cellular responses. The aim of this study was to elucidate whether the intensity and location of calreticulin overexpression in tumor cells are related to the elevated humoral immunity to calreticulin in patients with benign or malignant breast disease. Methods: This study involved 27 patients with benign and 58 patients with malignant breast tumors before surgical resection and 38 healthy volunteers. Cytoplasmatic or membranouscalreticulin overexpression in malignant or benign cells in paraffin-embedded tissues was determined using immunohistochemistry
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EC - Immunology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)